Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma

Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, particularly if they are transplantation or chimeric antigen receptor (CAR) T-cell ineligible, and novel therapeutics are needed. An 86-year-old woman with relapsed DLBCL received a novel, firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangha, Randeep, Davies, Neal M., Namdar, Afshin, Chu, Michael, Spratlin, Jennifer, Beauchamp, Erwan, Berthiaume, Luc G., Mackey, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947478/
https://www.ncbi.nlm.nih.gov/pubmed/35323358
http://dx.doi.org/10.3390/curroncol29030158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947478/
https://www.ncbi.nlm.nih.gov/pubmed/35323358
http://dx.doi.org/10.3390/curroncol29030158

Ejemplares similares